Search for a trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of ALKS 7119 in Healthy Adults

Primary:* Evaluate the safety and tolerability of ALKS 7119 following oral administration of multiple ascending doses of ALKS 7119 in healthy male and female adultsSecondary:* Evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ALKS 7119…

A Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ALKS 7119 in Healthy Male Adults

To evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ALKS 7119 following oral administration of single ascending doses of ALKS 7119 in healthy male adults

A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter
Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are
Asymptomatic At Risk for Developing Alzheimer*s Dementia

Primary Objective:The primary objective of this study is to determine whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive…

A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer*s Disease (Prodromal AD).

To assess the efficacy of two doses of MK-8931 based on overall clinical progression in subjects with prodromal Alzheimer's Disease (AD).To assess the efficacy of two doses of MK-8931 in slowing clinical decline and disease progression in…

Medical Nutrition in prodromal Alzheimer's Disease, a double-blind controlled 24-month study, with four times a 12 month extension study.

To evaluate the effect of Souvenaid® on cognition in patïents with mild cognitive impairment after 24 months.

A randomized, double-blind, placebo and reference controlled, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of Memogain administered by intranasal application to healthy elderly subjects.

Objective(s)• To evaluate the safety and tolerability after intranasal administration of ascending multiple doses of Memogain in healthy elderly subjects.• To evaluate the PK after intranasal administration of ascending multiple doses of Memogain in…

A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic 11C-PiB Positive Emission Tomography (PET) Amyloid Scanning

The primary objective is to assess the effects on amyloid plaque burden of administration of VX-745 for 12-weeks, as assessed by Dynamic 11C-PiB (Carbon-11 labeled Pittsburgh Compound B) PET Amyloid Scanning in patients with Mild Cogntitive…

A Phase I Partially Blinded Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivastigmine with Glycopyrrolate or Trospium in Healthy Elderly Volunteers

Primary:To establish the safety and tolerability of rivastigmine when given with concomitant glycopyrrolate at an accelerated dose escalation schedule up to 12 mg BID.To establish the safety and tolerability of rivastigmine when given with…

A Phase 3 Extension, Multicenter, Double-blind, Parallel-Group, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E E4 Noncarriers and Participated in Study 3133K1-3000-WW

Primary objectives: To evaluate the long-term safety and tolerability of IV administered bapineuzumab in subjects with AD.Secundary objectives: Efficacy. To explore the long-term efficacy of IV administered bapineuzumab in subjects with AD, using…

Dignity for nursing home patients: the influence of health care setting on dignity.

To further develop the dignity model in the nursing home setting by assessing which factors are especially relevant to dignity in this setting. The specific objective of this substudy is to develop a valid and reliable measurement instrument to…

A Phase 3 Extension, Multicenter, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers and Participated in Study 3133K1-3001-WW

Primary objectives: To evaluate the long-term safety and tolerability of IV administered bapineuzumab in subjects with AD.Secundary objectives:To explore the long-term efficacy of IV administered bapineuzumab in subjects with AD, using the following…

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild Alzheimer*s Disease

1. To demonstrate the clinical efficacy of leuco-methylthioninium bis(hydromethanesulfonate) (also known as LMTM,TRx0237) in mild Alzheimer*s disease as assessed by change from baseline on:• Alzheimer*s Disease Assessment Scale - Cognitive Subscale…

Efficacy and safety of delta-9-tetrahydrocannabinol (delta-THC) in behavioural disturbances in dementia

The primary objective is to evaluate the efficacy of Namisol® in the management of behavioural disturbances in patients with dementia. Secondary objectives are:- To evaluate the efficacy of Namisol® on secondary outcome measures, such as quality of…

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation

2.1 Primary Objectives• Evaluate the safety and tolerability of 2 fixed doses of FRM-0334 (300 and 500 mg daily in 2 sequential periods) over 28 days in subjects with prodromal to moderate FTD-GRN• Assess the PD effects of FRM-0334 on the change…

A single-center, open-label, randomized, 3-way crossover study to compare the rate and extent of Rivastigmine absorption from two different formulations of 7 day Rivastigmine transdermal systems (7-day RTS) with 24-hour Exelon® patches applied daily for 7 days in healthy male and female subjects.

To compare the rate and extent of rivastigmine absorption from two different formulations of 7-day rivastigmine transdermal systems (7-day RTS) with 24-hour Exelon® patch applied daily for 7 days in healthy adult male and female subjects.To assess…

Animal assisted interventions in dementia: effects on quality of life and neuropsychiatric symptoms.

The objective of this study is to determine the effects of protocolled interventions with a visiting dog or FurReal Friend (robotic toy animal) on quality of life and neuropsychiatric symptoms in patients with dementia.

Effects of a Neurofeedback Treatment on Psychological, Cognitive and Physiological (EEG) outcomes in patients suffering from cognitive decline

So far, only a few case-studies have been tried using neurofeedback in the treatment of dementia / cognitive decline. These indicate that there are behavioural changes and emotional changes next to cognitive changes. This will be the focus of this…

Collaborative dementia care, Strengthening and evaluation of early transitions: On the road to integrated care

1. To evaluete the clinical and cost effectiveness of 4 models of case management for persons with dementia and their main informal caregiver. 2. To evaluete the effectiveness of the 'dementiewjizer', an internet application that enables…

Healthy Aging: aerobic exercise, strength training and dementia.

The objective is to investigate the effects of a combined strength and aerobic exercise program on cognition, physical functioning, social functioning and ADL.

Effectiveness of Physioacoustic sound (PAS) therapy in demented nursing jome residents with nocturnal sleep distrurbances

nvt